INCY vs FTV Comparison

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Fortive Corp is a diversified industrial technology firm offering essential technologies, software, and services globally across several industries, such as manufacturing, utilities, medical, electronics, etc. It has two reportable segments: Intelligent Operating Solutions and Advanced Healthcare Solutions. Maximum revenue is generated from the Intelligent Operating Solutions segment, which offers professional instruments used in applications like maintenance, repair, measurement, and condition monitoring, connected worker safety, compliance solutions, etc. The products and services in this segment are marketed under various brands, including Fluke, Servicechannel, Gordian, Accruent, Industrial Scientific, and Intelex. Geographically, the firm generates maximum revenue from North America.